This ground-breaking agreement seeks to tackle the difficult and long-standing issues surrounding cardiovascular disease. It is aimed at finding effective ways to combat this life-threatening condition and drastically reduce its effects.
Evox Therapeutics Ltd, a prominent leader in the exosome therapeutics space, is pleased to announce its research collaboration and option agreement with Icahn School of Medicine at Mount Sinai in New York City. Through this exciting effort, the two parties will work towards creating exosome-encapsulated AAV (exoAAV) vectors for innovative gene delivery methods that could revolutionize the treatment of heart disease.
Evox and Icahn Mount Sinai have joined forces in the fight against cardiovascular diseases, bringing a cutting-edge solution with their revolutionary exoAAV technology. Harnessing the power of gene therapy, this top-of-the-line technology offers improved precision when targeting heart muscle cells, as well as a cleverly crafted immunity bypass. This groundbreaking approach has the potential to totally transform the way in which we approach cardiovascular treatments and could prove to be a game-changer for the field.
Dr. Susmita Sahoo, Associate Professor of Medicine, Cardiology at Icahn Mount Sinai, has made major breakthroughs in gene therapy through the use of exosomes. After years of research, her findings were published in the world-renowned cardiovascular disease journal Circulation on 6 July 2023.
Her success has opened greater possibilities for future collaborations, the latest of which is between Evox and Icahn Mount Sinai. The combination of Evox’s exosome technology with Icahn Mount Sinai’s expertise in gene delivery and cardiovascular research is sure to create a powerful force in the field of gene therapy.
Evox is taking a big step forward in treating diseases with exosome-mediated gene therapy, with the project of Dr. Sahoo and colleagues demonstrating the potential for successful delivery of AAV gene therapy directly to cardiomyocytes, even in the presence of significant anti-AAV antibodies.
This opens up the possibility of a gene therapy that can be used for any patient, regardless of their immune status. As Chief Executive Officer Dr. Antonin de Fougerolles puts it, Evox is “playing an important role in advancing this important research toward clinical impact”.
We are thrilled to be collaborating with Evox to explore the extraordinary possibilities of exosome-encapsulated AAVs as a potential gene therapy for heart disease. This research has the potential to represent a huge leap forward in the treatment of cardiac illness and revolutionize the field of gene therapy. Dr. Sahoo shares our enthusiasm and optimism for the potential of this work.
About Evox Therapeutics
Evox Therapeutics is leading the way in the cutting-edge field of exosome engineering, harnessing the power of extracellular vesicles (EVs) to develop a revolutionary new class of therapeutics for the treatment of life-threatening diseases. With its proprietary DeliverEX® technology, the Oxford-based biotechnology company is pushing boundaries and breaking ground in the field of drug delivery, providing safe, non-immunogenic and repeated delivery of medicines to parts of the body previously unreachable. Supported by leading venture capital firms and a comprehensive intellectual property portfolio, Evox is actively ushering in a new era in medicine.